DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dolobid (Diflunisal) - Indications and Dosage

 


Nutrilib.com
A comprihensive source of nutritional information

INDICATIONS AND USAGE

DOLOBID is indicated for acute or long-term use for symptomatic treatment of the following:

  1. Mild to moderate pain
  2. Osteoarthritis
  3. Rheumatoid arthritis

DOSAGE AND ADMINISTRATION

Concentration-dependent pharmacokinetics prevail when DOLOBID is administered; a doubling of dosage produces a greater than doubling of drug accumulation. The effect becomes more apparent with repetitive doses.

For mild to moderate pain, an initial dose of 1000 mg followed by 500 mg every 12 hours is recommended for most patients. Following the initial dose, some patients may require 500 mg every 8 hours.

A lower dosage may be appropriate depending on such factors as pain severity, patient response, weight, or advanced age; for example, 500 mg initially, followed by 250 mg every 8-12 hours.

For osteoarthritis and rheumatoid arthritis, the suggested dosage range is 500 mg to 1000 mg daily in two divided doses. The dosage of DOLOBID may be increased or decreased according to patient response.

Maintenance doses higher than 1500 mg a day are not recommended.

DOLOBID may be administered with water, milk or meals. Tablets should be swallowed whole, not crushed or chewed.

HOW SUPPLIED

Tablets DOLOBID are capsule-shaped, film-coated tablets supplied as follows:

No. 3390--250 mg peach colored, coded DOLOBID on one side and MSD 675 on the other.

NDC 0006-0675-61 unit of use bottles of 60

(6505-01-164-0501, 250 mg 60's).

No. 3392--500 mg orange colored, coded DOLOBID on one side and MSD 697 on the other.

NDC 0006-0697-61 unit of use bottles of 60

(6505-01-144-9724, 500 mg 60's).

                              7928833    Issued July 1998

COPYRIGHT © MERCK & CO., INC., 1988

All rights reserved

Page last updated: 2006-09-01

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008